June 17, 2025
Obesity in China is relatively rare but growing in prevalence. Here, a weight loss camp in Chengdu.
HECTOR RETAMAL/AFP via Getty Images

STAT+ | China, where obesity levels are low, becomes hotbed for weight loss drug trials

STAT’s Obesity Drug Tracker update looks at how China, a country with a low percentage of overweight people, became a hotbed of weight loss drug trials.

By Allison DeAngelis


STAT+ | FDA announces a new priority review program in bid to further administration goals

Recipients of a National Priority Voucher can expect decision in 1-2 months, down from 10-12, if a product aligns with FDA national health priorities.

By Lizzy Lawrence


STAT+ | Isomorphic Labs sets up U.S. presence, with an eye on clinical trials

Isomorphic Labs is setting up an office in Cambridge, Mass., as it prepares for clinical trials of some of its AI-enabled drug candidates.

By Katie Palmer



Bill Gates and his father, who died in 2020 of Alzheimer's disease.
Courtesy Bill & Melinda Gates Foundation/Dan Lamont

Opinion: Bill Gates: I lost my father to Alzheimer’s. But I’m more optimistic than ever about fighting the disease

“When we lost my dad, an Alzheimer’s diagnosis was a death sentence. Just five years later, that is finally starting to change,” writes Bill Gates.

By Bill Gates


STAT+ | Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion

The deal gives the Indianapolis-based drug giant access to experimental cardiovascular treatments being developed by Verve.

By Elaine Chen


Opinion: Obesity drugs don’t just offer weight loss. They give patients agency

Health isn’t just the sum of your metrics. It’s also the experience of living with purpose and possibility.

By David A. Shaywitz


Nabla founders, from left to right: Alex LeBrun, Delphine Groll, Martin Raison. Now Nabla is looking to expand its software that automates clinical note-taking to additional applications, like billing.

STAT+ | Nabla raises $70 million as market for AI tools to help doctors heats up

AI developer Nabla has raised $70 million as the company looks to expand the capabilities of its software that automates clinical documentation.

By Mario Aguilar


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Daily Recap? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.